Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIT-003
- Development stage
- Preclinical
- Lead developer
- MitoImmune Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MIT-003 is an oral drug candidate being developed by MitoImmune Therapeutics for the treatment of neurodegenerative diseases, specifically Alzheimer's Disease (AD) and Parkinson's Disease (PD). Currently in the discovery phase, the compound is part of MitoImmune's proprietary platform focused on mitochondrial modulation and the inhibition of ferroptosis. Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation, which has been implicated in the progression of various neurodegenerative conditions. By targeting mitochondrial dysfunction and preventing ferroptotic cell death, MIT-003 aims to provide neuroprotective therapeutic benefits.
Beyond the preview
Go deeper on MIT-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIT-003.